Elamipretide Trihydrochloride
Mitochondrial Disease
Floatz Rating
D30/100
Confidence
Indicative
Sponsor
Modality
protein_peptide
Development Phase
Unknown
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
15Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04689360CT.gov An Intermediate Size Expanded Access Protocol of Elamipretide | — | Available | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Mitochondrial Disease
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Elamipretide Trihydrochloride (this asset) | Unk | D · 30 | |
| Sonlicromanol | Khondrion BV | P3 | BB |
| Trimetazidine | Steen Hvitfeldt Poulsen | P4 | BB |
| Sodium Chloride | University Hospital, Strasbourg, France | P4 | BB |
| ARG | University Hospital, Strasbourg, France | P4 | BB |
| Efavirenz | The Cleveland Clinic | P4 | BB |
| NORVIR | The Cleveland Clinic | P4 | BB |
| Atazanavir | The Cleveland Clinic | P4 | B |
| Mitoquinol Mesilate | Mclean Hospital | P2/3 | B |
+9 more in the Mitochondrial Disease cohort
Other indications for Elamipretide Trihydrochloride
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Barth Syndrome | — | P4 | BBB · 72 |
| Friedreich Ataxia | — | P1/2 | CCC · 50 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Citation
Floatz Terminal. Elamipretide Trihydrochloride in Mitochondrial Disease. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/elamipretide-trihydrochloride-mitochondrial-disease
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →